Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study

Research output: Contribution to journalArticleAcademicpeer-review

42 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)269-277
Number of pages9
JournalEuropean Journal of Endocrinology
Volume179
Issue number5
DOIs
Publication statusPublished - 2018

Research programs

  • EMC MM-01-39-01
  • EMC MM-01-39-04

Cite this